← brief for 2026-09-12 · Slowing decline

Type 2 Diabetes: Chronic Clinical Metabolic Effects of SGLT2 Inhibitors.

Article A Not peer reviewed Meta-analysis or large trial

Key takeaways

This review chapter sums up what SGLT2 inhibitor drugs do over the long run in people with type 2 diabetes. It draws on large randomized trials with hard outcomes like kidney failure, heart failure and death. The benefits for the heart and kidneys show up even in people whose blood sugar was not very high to start with, so the drugs are doing more than lowering sugar. It is a summary of past trials, not a new study, and it does not give a single new effect size.

Who did this work

Scheen AJ

Source

Article · PubMed, the drug frontier · 2026 Aug 12
https://pubmed.ncbi.nlm.nih.gov/42730805/